Comparative Pharmacology
Head-to-head clinical analysis: CIPRODEX versus NEO FRADIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRODEX versus NEO FRADIN.
CIPRODEX vs NEO-FRADIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking bacterial DNA replication; dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension: 4 drops into affected ear(s) twice daily for 7 days.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
None Documented
None Documented
Ciprofloxacin: terminal elimination half-life 3-5 hours (prolonged to 5-10 hours in renal impairment). Dexamethasone: biological half-life 36-54 hours.
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
Ciprofloxacin: 50-70% renal (glomerular filtration and tubular secretion), 20-35% biliary/fecal. Dexamethasone: renal elimination of metabolites, <5% unchanged.
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Category C
Category C
Antibiotic/Corticosteroid Combination (Otic)
Antibiotic